- Founded
- 2020
- CEO
- Richard Francis
- Founders
- Prof. Moin Saleem
Prof. Mauro Giacca - % Shareholding
- 84%
- Stage
- Pre-clinical
- Raised in a Series A in November 2020
- £45m
Unless stated all financials at 30 June 2022
Purespring seeks to advance gene therapies for the treatment of chronic renal diseases that are currently poorly addressed with existing treatments.
Purespring is one of the first AAV gene therapy companies focused on the kidney globally and will seek to treat a number of debilitating chronic diseases that are currently poorly addressed with existing therapies. It has been founded around the seminal work of Professor Moin Saleem, Head of Bristol Renal where he heads a world leading group researching glomerular diseases.
Purespring has also established an in-vivo functional screening platform, FunSel, to initially screen for protective factors that could have applications across several kidney diseases. FunSel has been developed by Professor Mauro Giacca, a leader in gene therapy of cardiovascular disorders, and provides Purespring with a target discovery platform uniquely suited to systematically move gene therapy beyond monogenic disorders.
Investment thesis
- A number of chronic kidney diseases are poorly addressed by existing therapies, which are primarily based around the lowering of blood pressure and often progressing to dialysis and kidney transplantation.
- Purespring is developing disease modifying therapies for a number of monogenic and non-monogenic kidney diseases
Key risks
- Highly innovative concept in emerging space
-
Clinical risk by addressing non-monogenic disorders
Key risks are Syncona team view
The Purespring Therapeutics pipeline
-
Undisclosed programme
Syncona team
Chris Hollowood
Michael Kyriakides
Alice Renard
Purespring Therapeutics leaders and founders
Richard Francis
Moin Saleem
Other gene therapy portfolio companies
